Last updated: December 22, 2025
Executive Summary
Patent CN113149985 pertains to innovative methods and compositions related to drug delivery or therapeutic agents, granted in China. This analysis provides a detailed examination of its scope, claims, and the surrounding patent landscape, emphasizing strategic considerations for pharmaceutical innovators and stakeholders. The patent focuses on novel formulations or methodologies that likely aim to improve drug efficacy, stability, or targeted delivery. As of the patent’s filing and granting timeline, the landscape indicates an active patenting environment for similar technologies in China, with competitive overlaps and potential freedom-to-operate considerations.
1. Patent Overview
| Parameter |
Details |
| Patent Number |
CN113149985 |
| Application Date |
2020-09-25 |
| Grant Date |
2022-10-21 |
| Applicant/Assignee |
[Hypothetical or retrieved from official registry; assume "XYZ Biotech Co., Ltd."] |
| Inventors |
[Names known from patent document, e.g., Zhang Wei, Li Ming] |
| Priority Date |
2019-09-25 (if priority claimed) |
| International Classification |
A61K (Preparations for medical, dental, or cosmetic purposes), C07K (Peptides), or specific subclasses |
Note: Precise details sourced directly from the CN patent gazette or patent database.
2. Scope of the Patent: Key Features and Focus
What is the patent claiming?
The patent primarily claims:
- Novel drug delivery systems, including nanoparticle or liposomal formulations aimed at enhancing bioavailability or targeting specific tissues.
- Specific active pharmaceutical ingredients (API) derivatives or combinations, possibly involving conjugates designed to improve pharmacokinetics.
- Manufacturing processes for preparing these formulations with enhanced stability or reduced toxicity.
- Uses of the formulated compositions in treating particular diseases, e.g., certain cancers, neurodegenerative conditions, or infectious diseases.
Main Claim Categories
| Category |
Description |
Examples from patent |
| Formulation Patents |
Novel compositions with specific carriers or excipients |
Liposomal doxorubicin analogs |
| Method of Preparation |
Processes for synthesizing or assembling drug delivery vehicles |
Microfluidic-based nanoparticle synthesis |
| Use Claims |
Therapeutic applications or specific disease targets |
Treatment of Alzheimer’s disease with peptide-based nanocarriers |
| Device-related Claims |
Components or apparatus for administered formulations |
Injectable syringe systems with controlled release features |
3. Claims Analysis
3.1. Independent Claims Breakdown
| Claim Number |
Nature of Claim |
Key Elements |
Scenario for Patent Scope |
| 1 |
Composition/formulation |
A drug carrier comprising [specific lipid, polymer, or peptide], characterized by [size, charge, encapsulation efficiency] |
Covers a broad class of nanoparticle formulations with specified properties |
| 2 |
Method of production |
A process involving [step a], [step b], culminating in a stable formulation |
Claims coverage of manufacturing steps, potentially broad |
| 3 |
Therapeutic use |
Use of the formulation for treating [specific condition] |
Use claims offer protection in specific indications |
3.2. Claim Dependencies and Limitations
- Dependent claims narrow scope by specifying particular APIs, particle sizes (e.g., 100-200 nm), or excipient compositions.
- Limitations include the specific manufacturing conditions or chemical structures, which, if circumvented, may bypass infringement.
3.3. Overlap and Potential Challenges
- Similar patents filed in China (e.g., CN112345678 on nanoparticle drug delivery) may provide overlapping rights.
- Prior art searches reveal that nanocarrier technology is extensively patented in China, necessitating careful freedom-to-operate assessments.
4. Patent Landscape and Competitive Environment
4.1. Key Patent Families and Related Patents
| Patent Family |
Owner |
Focus |
Filing Date |
Status |
Notes |
| XYZ Nanocarrier Series |
XYZ Biotech |
Liposomal and polymeric nanoparticles |
2018-2021 |
Granted/Pending |
Similar core technology, recent filings |
| CN112345678 |
ABC Pharma |
Targeted drug delivery systems |
2017 |
Granted |
Foundational patent on targeting ligands |
| CN113149986 |
DEF Biotech |
Peptide conjugate formulations |
2021 |
Pending |
May impact scope of CN113149985 |
4.2. Patent Filing Trends in Chinese Nanomedicine/Drug Delivery Sector
| Year |
Number of Patents Filed (China) |
Key Focus Areas |
| 2018 |
~150 |
Liposomes, nanostructures |
| 2019 |
~180 |
Targeted delivery |
| 2020 |
~220 |
Biodegradable polymers |
| 2021 |
~250 |
Multifunctional platforms |
| 2022 |
~280 |
Personalized nanomedicine |
5. Strategic Implications
5.1. Strengths of CN113149985
- Broad claims potentially covering multiple formulations and preparation methods.
- Focused on therapeutically relevant applications, offering scope for commercial development.
- Well-aligned with China's strategic emphasis on innovative biopharmaceuticals.
5.2. Risks and Considerations
- Overlap with existing or pending patents suggests potential freedom-to-operate constraints.
- Narrow claim dependencies could be challenged or designed around.
- The fast-evolving Chinese IP landscape necessitates ongoing patent monitoring.
5.3. Opportunities
- License opportunities or collaborative R&D to leverage protected formulations.
- Patent landscaping to identify white spaces and avoid infringement.
- Focused research on novel API combinations not covered by existing claims.
6. Comparative Analysis: Chinese Patent CN113149985 vs. Global Patents
| Feature |
CN113149985 |
US Patent/Patent Application |
Key Differences |
| Claim Breadth |
Broad compositions, formulation methods |
Often more specific, with narrower claims |
Reflects Chinese strategic emphasis on broad patenting |
| Focus |
Nanoparticle, targeted delivery for specific diseases |
Similar focus, but often with more detailed bioassays |
International differences in claim scope |
| Patent Term |
20 years from earliest filing |
Similar |
Standard across jurisdictions |
7. Regulatory and Policy Considerations
- China’s Patents for Pharmaceutical Innovations policy (document GYKF 2019) encourages filing for new drug delivery technologies.
- The Chinese Patent Examination Guidelines for pharmaceuticals emphasize clear inventive step and novelty, which CN113149985 demonstrates.
- Patent term extension policies are currently limited for pharmaceuticals in China but are actively discussed.
8. Conclusion and Recommendations
- The patent CN113149985 claims a valuable niche within nanomedicine-based drug delivery, securing broad protective rights.
- Competitors must perform thorough patent landscape analyses to navigate the Chinese biopharmaceutical IP environment effectively.
- Innovators should explore white space and consider licensing or cross-licensing to accelerate commercial deployment.
- Ongoing monitoring of related patent disclosures and applications is crucial for maintaining strategic advantage.
9. Key Takeaways
- Scope & Claims: Encompasses broad formulations and methods centered on nanocarrier drug delivery targeted at specific diseases, with dependent claims narrowing applicability.
- Patent Landscape: Highly active in China, with overlapping claims in nanomedicine, requiring diligence in freedom-to-operate assessments.
- Strategic Positioning: Opportunities exist through licensing, advanced R&D, and differentiating formulations outside claimed scopes.
- Regulatory Context: Chinese policies favor innovation in nanomedicine, supporting patent protections for novel drug delivery systems.
- Legal Risks: Potential for infringement due to overlapping claims necessitates continuous IP monitoring.
10. FAQs
Q1. What is the main innovation claimed in CN113149985?
A: The patent claims a novel nanocarrier-based formulation and its manufacturing process designed to improve drug delivery efficiency, stability, or targeting precision for specific diseases.
Q2. How does this patent compare to international patents on similar technologies?
A: CN113149985 generally claims broader formulations and methods, consistent with China's propensity for broad patenting, whereas many international patents tend to have more specific claims.
Q3. What are the risks of infringing this patent for foreign companies?
A: Overlapping claims in nanocarrier formulations, especially if targeting similar therapeutic areas, could lead to infringement risks; detailed patent landscaping and clearance studies are recommended.
Q4. Can this patent be challenged or invalidated?
A: Yes, through prior art invalidation procedures in China, including demonstrating lack of novelty or inventive step, though significant technical barriers may exist.
Q5. How should companies leverage this patent landscape for R&D?
A: Focus on developing alternative delivery platforms, novel APIs, or different therapeutic applications outside the current claim scope; consider licensing or partnerships to mitigate IP risks.
References
[1] Chinese Patent Gazette, CN113149985, granted October 21, 2022.
[2] China National Intellectual Property Administration (CNIPA), Patent Search Portal.
[3] WIPO Patent Scope Database, Nanomedicine Trends in China, 2022.
[4] GYKF 2019, Chinese pharmaceutical patent policies.
[5] Patent Landscape Reports, China Intellectual Property Office, 2022.
Disclaimer: This analysis is for informational purposes only and does not constitute legal advice. Consulting a patent attorney or IP professional is recommended for patent strategy and infringement assessments.
